Changes in Immune‐Inflammation Status and Prognosis in Pregnancy‐Related Cerebral Venous Thrombosis Authors: Xiaoming Zhang, Zilin Xu, Ran Duan, Chunxiao Lu, Da Zhou, Chen Zhou, Ran Meng, Xunming Ji Published: 2026 ABSTRACT ABSTRACTObjectiveDistinguishing pathological changes from physiological adaptations in pregnancy‐related cerebral venous thrombosis (CVT) is clinically challenging. This study aimed to characterize coagulation, immune‐inflammation, and dehydration status in these patients and assess their prognostic value.MethodsIn this retrospective study, 120 participants were categorized into four groups: CVT with pregnancy‐puerperium, CVT without pregnancy‐puerperium, pregnancy‐puerperium without CVT, and healthy nonpregnant female controls (30 per group). Laboratory indices were compared across groups. Neurological severity and functional outcomes were assessed using the National Institutes of Health Stroke Scale (NIHSS) and the modified Rankin Scale (mRS) at admission, 7 days, and 3 months.ResultsCompared with CVT without pregnancy‐puerperium, CVT with pregnancy‐puerperium presented earlier after symptom onset and exhibited more severe neurological manifestations. CVT with pregnancy‐puerperium showed higher fibrinogen and D‐dimer levels than CVT without pregnancy‐puerperium and healthy nonpregnant controls, but these markers overlapped with healthy pregnancy‐puerperium controls. Several inflammatory markers were elevated compared with non‐pregnancy groups, while neutrophil count, NLR, SII, and CRP overlapped with healthy pregnancy‐puerperium controls. Elevated urine specific gravity was more frequent in CVT with pregnancy‐puerperium than in healthy pregnancy‐puerperium controls. Within this group, D‐dimer and inflammatory markers correlated positively with NIHSS and mRS scores at admission and 7 days. Plasma osmolality > 310 mOsm/(kg·H2O) was associated with worse neurological outcomes at 7 days and 3 months.InterpretationCVT during pregnancy‐puerperium occurs against pregnancy‐related hypercoagulability, immune‐inflammatory activation, and fluid‐balance changes, with overlap between pathological CVT‐related changes and physiological pregnancy adaptations. D‐dimer, inflammatory indices, and dehydration‐related parameters may provide prognostic information for risk stratification.Keywords: cerebral venous thrombosis, coagulation, dehydration, inflammation, prognosis Abbreviations activated partial thromboplastin time body mass index C‐reactive protein computed tomography venography Cerebral venous thrombosis digital subtraction angiography interleukin‐6 potassium lymphocyte‐to‐monocyte ratio magnetic resonance black‐blood thrombus imaging the modified Rankin Scale magnetic resonance venography sodium the National Institutes of Health Stroke Scale neutrophil‐to‐lymphocyte ratio platelet‐to‐lymphocyte ratio prothrombin time systemic immune‐inflammation index thrombin time uric acid urine specific gravity Introduction Cerebral venous thrombosis (CVT) is an uncommon but potentially devastating form of cerebrovascular disease, accounting for approximately 0.5%–3% of all strokes and predominantly affecting young and middle‐aged adults, particularly women of childbearing age [1, 2, 3, 4, 5, 6]. Pregnancy and the puerperium represent a major risk window, contributing to nearly one‐fifth of adult CVT cases and being associated with substantial morbidity and mortality [7, 8, 9]. Laboratory biomarkers play an important role in the diagnosis and clinical assessment of CVT. Markers of coagulation activation, such as D‐dimer and fibrinogen, reflect thrombus formation and fibrinolysis; inflammatory indices, including leukocyte and neutrophil counts, neutrophil‐to‐lymphocyte ratio (NLR), C‐reactive protein (CRP), and interleukin‐6 (IL‐6), indicate systemic inflammatory responses accompanying venous thrombosis and dehydration‐related parameters, such as urine specific gravity (USG), creatinine, urea, and plasma osmolality, may reflect hemoconcentration and impaired venous flow [10, 11, 12, 13, 14, 15]. In nonpregnant populations, these biomarkers have been associated with disease severity and clinical outcomes in CVT. However, the interpretation of these laboratory indices becomes fundamentally challenging during pregnancy and the puerperium. Pregnancy is characterized by profound physiological alterations, including a hypercoagulable state with increased coagulation factor levels, adaptive immune modulation with low‐grade systemic inflammation, and marked changes in plasma volume and renal handling of fluids [16, 17, 18, 19]. As a result, laboratory patterns that typically signal pathological thrombosis, inflammation, or dehydration in the general population may partially or entirely overlap with normal pregnancy‐related physiology. This overlap creates substantial diagnostic ambiguity and complicates the clinical assessment of CVT in pregnant and postpartum women. Despite the clinical importance of this issue, existing studies have largely examined CVT‐related biomarkers either in mixed populations or without adequate physiological controls. To date, no study has systematically disentangled pathological CVT‐associated laboratory alterations from pregnancy‐related physiological changes across the major biological pathways implicated in CVT‐coagulation, inflammation, and dehydration status nor comprehensively evaluated their associations with neurological severity and outcomes specifically in pregnancy‐related CVT. To address these gaps, we conducted a retrospective study comparing coagulation, inflammatory, and dehydration‐related laboratory indices across four well‐defined groups: patients with CVT during pregnancy or puerperium (CVT with pregnancy‐puerperium), CVT without pregnancy‐puerperium, pregnancy‐puerperium without CVT and healthy nonpregnant female controls. Our objectives were twofold: first, to identify laboratory parameters that retain diagnostic and pathophysiological relevance for CVT in the context of pregnancy and puerperium and second, to determine whether biomarkers from these pathways are associated with disease severity and clinical outcomes in CVT with pregnancy‐puerperium. Patients and Methods Study Population This retrospective study was conducted in the Department of Neurology at Xuanwu Hospital, Capital Medical University. Consecutive participants were enrolled between November 2021 and September 2025 and categorized into four groups: (1) CVT with pregnancy‐puerperium; (2) CVT without pregnancy‐puerperium; (3) healthy pregnant or puerperal women; and (4) healthy nonpregnant female controls. Each group included 30 participants. The diagnosis of CVT was confirmed using magnetic resonance venography (MRV), computed tomography venography (CTV), magnetic resonance black‐blood thrombus imaging (MRBTI), or digital subtraction angiography (DSA). Patients were excluded if they had severe systemic illness, a history of arterial stroke other than CVT, any bacterial or viral infection in the past month, high fever, dehydration, and sweating caused by any reason, renal dysfunction, or incomplete clinical/laboratory data. Healthy pregnant or puerperal controls were recruited from routine antenatal or postnatal clinics and had no clinical symptoms or imaging findings suggestive of CVT. Healthy nonpregnant female controls were age‐matched women who had no history of any bacterial or viral infection in the past month, stroke, malignancy, major trauma, or renal disease. The study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Ethics Committee of Xuanwu Hospital. Written informed consent was obtained from all participants or their legal representatives. Data Collection Demographic and clinical data were extracted from electronic medical records, including age, body mass index (BMI), vascular risk factors, comorbidities, obstetric characteristics (when applicable), clinical presentation, and neuroimaging findings. Neuroimaging data regarding venous sinus involvement were independently reviewed by two experienced neuroradiologists who were blinded to clinical information; discrepancies were resolved by consensus. For patients with CVT, venous blood samples were collected within 1–2 days after hospital admission. For control participants, blood samples were obtained during routine health examinations or antenatal/postnatal visits. Laboratory assays included coagulation parameters (prothrombin time [PT], activated partial thromboplastin time [APTT], thrombin time [TT], fibrinogen, and D‐dimer), inflammatory markers (neutrophil, lymphocyte, and monocyte counts, NLR, lymphocyte‐to‐monocyte ratio [LMR], platelet‐to‐lymphocyte ratio [PLR], systemic immune‐inflammation index [SII], CRP, and IL‐6), and dehydration‐related indices (Cr, urea, USG, hematocrit, serum sodium [Na+], potassium [K+], glucose, uric acid [UA], UA/Cr ratio, and calculated plasma osmolality [2 × (Na++K+) + glucose + urea]). Neurological severity and functional outcome were assessed using the National Institutes of Health Stroke Scale (NIHSS) and the modified Rankin Scale (mRS) at admission, 7 days, and 3 months. At the 3‐month follow‐up, residual somatic symptoms (including headache, seizure recurrence, and visual disturbances) and mental symptoms (including depression, anxiety, and sleep disturbances) were systematically recorded. Statistical Analysis Statistical analyses were performed using Stata 15.1 (StataCorp, College Station, TX, USA). The normality of continuous variables was assessed using the Shapiro–Wilk test. Normally distributed variables are presented as mean ± standard deviation, whereas non‐normally distributed variables are expressed as median with interquartile range. Group comparisons for continuous data were conducted using Student's t‐test (two groups) or one‐way ANOVA (multiple groups) for parametric data, and the Mann–Whitney U test (two groups) or Kruskal–Wallis test (multiple groups) for nonparametric data. Categorical variables are reported as numbers (percentages) and were compared using the chi‐square test or Fisher's exact test, as appropriate. Spearman's rank correlation coefficient was used to evaluate associations between laboratory indices and clinical severity/prognosis scores (NIHSS and mRS) across different time points, as well as with residual symptoms at 3 months. Missing data (affecting < 10% of any variable) were imputed using the mean for continuous variables or the mode for categorical variables. A two‐sided p value < 0.05 was considered statistically significant. To control for Type I errors due to multiple comparisons among the three groups, the significance level α was adjusted using the Bonferroni method (corrected α = 0.0167). Results Patient Characteristics A total of 120 participants were included in this retrospective analysis: 30 patients had CVT with pregnancy‐puerperium (Group 1), 30 cases of CVT without pregnancy‐puerperium (Group 2), 30 healthy pregnant or puerperal women (Group 3), and 30 healthy nonpregnant female controls (Group 4). Comparisons between the two CVT groups (Group 1 vs. Group 2) revealed no significant differences in age, BMI, or most comorbidities, although the interval from symptom onset to hospital admission was significantly shorter in Group 1 (p < 0.001). When compared with Group 3, Group 1 demonstrated a significantly lower BMI (p = 0.001) and a lower prevalence of diabetes (p = 0.044). Regarding pregnancy characteristics, CVT in Group 1 occurred more frequently during the first trimester (p < 0.001) and less frequently during the third trimester (p < 0.001). There was no significant difference in parity between Group 1 and Group 3 (primiparity: 80.00% vs. 76.67%, p = 0.754). Clinically, headache was highly prevalent in both CVT groups (86.67% each), but it was rare in Group 3 (3.33%, p < 0.001). Neurological deficits, seizures and unconsciousness were more common in Group 1 than in both Groups 2 and 3 (all p < 0.05). In contrast, visual disorders (63.33%, p < 0.001) and tinnitus (26.67%, p = 0.002) were more frequent in Group 2. Dizziness and diplopia did not differ significantly among the groups. Imaging findings indicated that involvement of the right transverse sinus, superior sagittal sinus, and straight sinus was more common in Group 1, whereas cortical vein involvement was predominated in Group 2 (53.33%, p = 0.035). Although NIHSS and mRS scores on admission did not differ statistically between the two CVT groups, the upper quartile values were notably higher in Group 1 (NIHSS 6.00 vs. 1.00; mRS 3.25 vs. 2.00). The overall study design, biomarker domains, and key clinical interpretation are summarized in Figure 1. Baseline clinical characteristics are presented in Table 1. Study design and main findings. Four groups were compared: CVT with pregnancy‐puerperium (Group 1), CVT without pregnancy‐puerperium (Group 2), healthy pregnant/puerperal women (Group 3), and healthy nonpregnant female controls (Group 4). Laboratory assessments covered coagulation (fibrinogen, D‐dimer), inflammation (NLR, CRP), and dehydration (USG > 1.03). Compared with Group 2 and Group 4, Group 1 showed higher coagulation and inflammatory markers, while selected coagulation and inflammatory markers overlapped with Group 3. Elevated USG was more frequent in Group 1 versus Group 3. Within Group 1, D‐dimer, inflammatory markers, and plasma osmolality > 310 mOsm/(kg·H2O) were associated with worse neurological severity and outcomes. TABLE 1Characteristics of the enrolled participants.CharacteristicsGroup 1: CVT during pregnancy and puerperium (n = 30)Group 2: CVT without pregnancy and puerperium (n = 30)Group 3: Healthy pregnant or puerperal women (n = 30) p 1 p 2 DemographicsAge, year30.43 ± 5.1031.63 ± 6.1131.67 ± 3.420.3540.341BMI24.58 ± 4.0324.42 ± 4.3628.62 ± 5.200.8940.001 a Days from onset to hospital admission10.00 [4.00, 28.50]45.00 [20.00, 127.50]—< 0.001 a —Hypertension, n (%)4 (13.30)1 (3.33)9 (30.00)0.1610.117Diabetes, n (%)1 (3.33)0 (0.00)6 (20.00)0.3130.044Hyperlipoidemia, n (%)5 (16.67)1 (3.33)1 (3.33)0.0850.085Gestational weeks, n (%)First trimester14 (46.67)—1 (3.33)—< 0.001 a Second trimester4 (13.33)—6 (20.00)—0.488Third trimester3 (10.00)—17 (56.67)—< 0.001 a Puerperium9 (30.00)—6 (20.00)—0.371Parity, n (%)Primiparity24 (80.00)—23 (76.67)—0.754Multiparity6 (20.00)—7 (23.33)—0.754Clinical manifestation, n (%)Headache26 (86.67)26 (86.67)1 (3.33)1.000< 0.001 b Nausea or vomiting16 (53.33)11 (36.67)7 (23.33)0.1940.017Dizziness4 (13.33)8 (26.67)2 (6.67)0.1970.671Tinnitus0 (0.00)8 (26.67)1 (3.33)0.002 b 0.313Neurological deficits10 (33.33)3 (10.00)0 (0.00)0.028< 0.001 b Visual disorder5 (16.67)19 (63.33)0 (0.00)< 0.001 b 0.020Diplopia1 (3.33)2 (6.67)0 (0.00)0.5540.313Seizures14 (46.67)1 (3.33)0 (0.00)< 0.001 b < 0.001 b Unconsciousness18 (60.00)1 (3.33)0 (0.00)< 0.001 b < 0.001 b Involved sinus, n (%)Right transverse sinus12 (40.00)14 (46.67)—0.602—Left transverse sinus15 (50.00)19 (63.33)—0.297—Right sigmoid sinus11 (36.67)7 (23.33)—0.260—Left sigmoid sinus12 (40.00)13 (43.33)—0.793—Superior sagittal sinus14 (46.67)8 (26.67)—0.108—Straight sinus6 (20.00)2 (6.67)—0.255—Cortical vein8 (26.67)16 (53.33)—0.035 a —NIHSS at admission0.00 [0.00, 6.00]0.00 [0.00, 1.00]—0.145—mRS at admission1.00 [1.00, 3.25]1.00 [1.00, 2.00]—0.115— Note: 1—Group 1 versus Group 2; 2—Group 1 versus Group 3.Abbreviations: BMI, body‑mass index; mRS, the modified Rankin Scale; NIHSS, the National Institutes of Health Stroke Scale. a p < 0.05 considered statistically significant. b To control the Type I errors, the significance level was adjusted, with p < 0.0167 (0.05/3) considered statistically significant. Characteristics of the enrolled participants. Note: 1—Group 1 versus Group 2; 2—Group 1 versus Group 3. Abbreviations: BMI, body‑mass index; mRS, the modified Rankin Scale; NIHSS, the National Institutes of Health Stroke Scale. p < 0.05 considered statistically significant. To control the Type I errors, the significance level was adjusted, with p < 0.0167 (0.05/3) considered statistically significant. Coagulation Parameters The coagulation profile of Group 1 demonstrated significantly elevated fibrinogen (4.0 [3.4, 4.8] g/L) and D‐dimer (1.4 [0.8, 2.5] mg/L) levels compared to both Group 2 (fibrinogen 2.9 [2.4, 3.2] g/L, D‐dimer 0.2 [0.1, 0.4] mg/L) and Group 4 (fibrinogen 2.9 [2.5, 3.3] g/L, D‐dimer 0.2 [0.1, 0.2] mg/L), all p < 0.001 (Table 2). In contrast, PT, APTT, and TT showed no significant differences across the three groups. When compared to Group 3, Group 1 showed prolonged PT (13.6 [13.1, 14.8] vs. 12.8 [12.6, 13.2] s), APTT (37.1 [32.8, 39.7] vs. 31.4 [29.8, 34.4] s), and TT (16.1 [15.3, 17.4] vs. 15.0 [14.5, 15.5] s), all p < 0.001 (Table 3). Although the fibrinogen level was lower in Group 1 than in Group 3 (4.0 [3.4, 4.8] vs. 4.8 [4.3, 5.6] g/L, p = 0.007), it remained higher than in Group 4 (p < 0.001). The D‐dimer level did not differ between Groups 1 and 3 (1.4 [0.8, 2.5] vs. 1.2 [0.7, 1.8] mg/L, p = 0.625), yet both Groups 1 and 3 had markedly higher levels than Group 4 (both p < 0.001). TABLE 2Comparison of laboratory indices among CVT during pregnancy and the puerperium (Group 1), CVT without pregnancy and puerperium (Group 2), and healthy nonpregnant female controls (Group 4).IndicesGroup 1: CVT during pregnancy and puerperium (n = 30)Group 2: CVT without pregnancy and puerperium (n = 30)Group 4: Healthy female controls without pregnancy and puerperium (n = 30) p 1 p 2 p 3 Coagulation‐relatedPT13.6 [13.1, 14.8]13.6 [13.0, 14.3]13.3 [13.0, 13.6]0.9510.0580.050APTT37.1 [32.8, 39.7]38.4 [34.8, 43.1]35.1 [32.8, 39.1]0.1080.4470.018TT18.9 ± 11.616.3 ± 1.516.3 ± 0.90.1450.1400.986Fib4.0 [3.4, 4.8]2.9 [2.4, 3.2]2.9 [2.5, 3.3]< 0.001 b < 0.001 b 0.900D‐D1.4 [0.8, 2.5]0.2 [0.1, 0.4]0.2 [0.1, 0.2]< 0.001 b < 0.001 b 0.163Inflammation‐relatedneutrophil6.8 [4.2, 9.6]3.4 [2.1, 4.1]2.9 [1.9, 3.8]< 0.001 b < 0.001 b 0.250leukomonocyte1.5 ± 0.61.8 ± 0.61.9 ± 0.60.0560.027 a 0.748monocyte0.4 [0.3, 0.6]0.4 [0.3, 0.4]0.3 [0.3, 0.4]0.018< 0.001 b 0.148NLR4.5 [2.5, 8.8]1.8 [1.3, 2.6]1.6 [1.2, 2.1]< 0.001 b < 0.001 b 0.276LMR3.7 ± 2.05.3 ± 2.26.1 ± 2.30.003 a < 0.001 a 0.173PLR153.3 [98.2, 207.7]138.2 [106.4, 189.1]113.3 [88.0, 180.7]0.9650.1200.109SII877.4 [374.0, 2029.9]443.1 [340.1, 652.5]360.7 [215.6, 530.7]0.004 b < 0.001 b 0.085CRP14.5 [5.8, 22.5]2.0 [1.8, 4.0]1.5 [1.0, 2.0]< 0.001 b < 0.001 b 0.031IL‐68.8 [6.1, 22.8]2.6 [1.5, 5.5]2.4 [1.5, 3.4]< 0.001 b < 0.001 b 0.129Dehydration‐relatedCr40.0 [38.0, 50.3]47.5 [44.0, 53.0]51.5 [41.8, 58.3]0.0240.002 b 0.384Urea2.9 ± 1.33.4 ± 1.004.1 ± 1.20.107< 0.001 a 0.012 a USG1.0 [1.0, 1.0]1.0 [1.0, 1.0]1.0 [1.0, 1.0]0.8770.9790.855Hematocrit, %34.9 ± 3.735.8 ± 3.537.2 ± 3.30.3150.012 a 0.121Na+ 139.4 [136.8, 141.4]140.0 [138.0, 141.3]141.1 [140.0, 142.0]0.5610.007 b 0.034K+ 3.7 [3.6, 3.9]3.8 [3.6,4.0]3.8 [3.6, 4.0]0.7420.2670.435Glucose4.5 [4.0, 5.7]4.5 [4.1, 4.7]4.4 [4.1, 4.8]0.6460.3390.619Uric acid241.0 [165.5, 314.0]270.5 [234.8, 317.3]251.5 [215.3, 300.5]0.0890.5430.269UA/Cr5.6 [4.2, 7.4]5.8 [4.9, 6.7]4.9 [4.1, 5.9]0.5900.1400.042Plasma osmolality, mOsm/(kg·H2O)293.4 [288.6, 298.4]295.4 [292.1, 298.0]297.9 [296.2, 299.5]0.5030.001 b 0.008 b USG > 1.03, n (%)10 (33.3)4 (13.3)0 (0.00)0.0670.001 b 0.038Plasma osmolality > 310mOsm/(kg·H2O)2 (6.67)0 (0.00)1 (3.33)0.1500.5540.313 Note: 1—Group 1 versus Group 2; 2—Group 1 versus Group 4; 3—Group 2 versus Group 4.Abbreviations: APTT, activated partial thromboplastin time; Cr, creatinine; CRP, C‐reactive protein; D‐D, D‑dimer; Fib, fibrinogen; IL‑6, interleukin‐6; LMR, lymphocyte‑to‑monocyte ratio; NLR, neutrophil‐to‐lymphocyte ratio; PLR, platelet‑to‑lymphocyte ratio; PT, prothrombin time; SII, systemic immune‑inflammation index; TT, thrombin time; UA, uric acid; USG, urine specific gravity. a p < 0.05 considered statistically significant. b To control the Type I errors, the significance level was adjusted, with p < 0.0167 (0.05/3) considered statistically significant. Comparison of laboratory indices among CVT during pregnancy and the puerperium (Group 1), CVT without pregnancy and puerperium (Group 2), and healthy nonpregnant female controls (Group 4). Note: 1—Group 1 versus Group 2; 2—Group 1 versus Group 4; 3—Group 2 versus Group 4. Abbreviations: APTT, activated partial thromboplastin time; Cr, creatinine; CRP, C‐reactive protein; D‐D, D‑dimer; Fib, fibrinogen; IL‑6, interleukin‐6; LMR, lymphocyte‑to‑monocyte ratio; NLR, neutrophil‐to‐lymphocyte ratio; PLR, platelet‑to‑lymphocyte ratio; PT, prothrombin time; SII, systemic immune‑inflammation index; TT, thrombin time; UA, uric acid; USG, urine specific gravity. p < 0.05 considered statistically significant. To control the Type I errors, the significance level was adjusted, with p < 0.0167 (0.05/3) considered statistically significant. TABLE 3Comparison of laboratory indices among patients with CVT during pregnancy and the puerperium (Group 1), healthy pregnant or puerperal women (Group 3), and healthy female controls without pregnancy and puerperium (Group 4).IndicesGroup 1: CVT during pregnancy and puerperium (n = 30)Group 3: Healthy pregnant or puerperal women (n = 30)Group 4: Healthy female controls without pregnancy and puerperium (n = 30) p 1 p 2 p 3 Coagulation‐relatedPT13.6 [13.1, 14.8]12.8 [12.6, 13.2]13.3 [13.0, 13.6]< 0.001 b 0.1070.015 b APTT37.1 [32.8, 39.7]31.4 [29.8, 34.4]35.1 [32.8, 39.1]< 0.001 b 0.630< 0.001 b TT16.1 [15.3, 17.4]15.0 [14.5, 15.5]16.5 [15.5, 16.8]< 0.001 b 0.982< 0.001 b Fib4.0 [3.4, 4.8]4.8 [4.3, 5.6]2.9 [2.5, 3.3]0.007 b < 0.001 b < 0.001 b D‐D1.4 [0.8, 2.5]1.2 [0.7, 1.8]0.2 [0.1, 0.2]0.625< 0.001 b < 0.001 b Inflammation‐relatedneutrophil6.8 [4.2, 9.6]7.9 [5.2, 9.0]2.9 [1.9, 3.8]0.432< 0.001 b < 0.001 b leukomonocyte1.5 ± 0.61.5 ± 0.51.9 ± 0.60.7770.015 a 0.007 a monocyte0.4 [0.3, 0.6]0.4 [0.4, 0.6]0.3 [0.3, 0.4]0.955< 0.001 b < 0.001 b NLR4.5 [2.5,8.8]5.0 [3.7,6.8]1.6 [1.2, 2.1]0.450< 0.001 b < 0.001 b LMR3.5 [2.2, 5.0]3.2 [2.5, 4.3]6.1 [4.3, 7.7]0.771< 0.001 b < 0.001 b PLR153.3 [98.2, 207.7]135.0 [110.6, 190.2]113.3 [88.0, 180.7]0.9250.1170.141SII877.4 [374.0, 2029.9]1139.9 [668.7, 1487.3]360.7 [215.6, 530.7]0.635< 0.001 b < 0.001 b CRP14.5 [5.8, 22.5]6.0 [4.0, 14.0]1.5 [1.0, 2.0]0.271< 0.001 b < 0.001 b Dehydration‐relatedCr40.0 [38.0, 50.3]46.0 [40.0, 51.5]51.5 [41.8, 58.3]0.1360.001 b 0.089Urea2.9 ± 1.33.2 ± 0.94.1 ± 1.20.337< 0.001 b 0.001 b USG1.0 [1.0, 1.0]1.0 [1.0, 1.0]1.0 [1.0, 1.0]0.002 b 0.713< 0.001 b Hematocrit, %34.9 ± 3.735.4 ± 3.437.2 ± 3.30.5380.011 a 0.052Na+ 139.4 [136.8, 141.4]137.8 [136.6, 139.5]141.1 [140.0, 142.0]0.0620.005 b < 0.001 b K+ 3.7 [3.6, 3.9]3.9 [3.7, 4.0]3.8 [3.6, 4.0]0.0560.33310.346Glucose4.5 [4.0, 5.7]4.9 [4.0, 5.4]4.4 [4.1, 4.8]0.6320.3400.152Uric acid241.0 [165.5, 314.0]303.5 [233.5, 341.3]251.5 [215.3, 300.5]0.0280.6180.087UA/Cr5.6 [4.2, 7.4]6.4 [5.0, 7.5]4.9 [4.1, 5.9]0.1530.1210.003 b Plasma osmolality, mOsm/(kg·H2O)293.4 [288.6, 298.4]291.4 [289.4, 294.6]297.9 [296.2, 299.5]0.1200.001 b < 0.001 b USG > 1.03, n (%)10 (33.3)0 (0.00)0 (0.00)0.001 b 0.001 b —Plasma osmolality > 310 mOsm/(kg·H2O)2 (6.67)0 (0.00)1 (3.33)0.1500.5540.313 Note: 1—Group 1 versus Group 3; 2—Group 1 versus Group 4; 3—Group 3 versus Group 4.Abbreviations: APTT, activated partial thromboplastin time; Cr, creatinine; CRP, C‐reactive protein; D‐D, D‑dimer; Fib, fibrinogen; IL‑6, interleukin‐6; LMR, lymphocyte‑to‑monocyte ratio; NLR, neutrophil‐to‐lymphocyte ratio; PLR, platelet‑to‑lymphocyte ratio; PT, prothrombin time; SII, systemic immune‑inflammation index; TT, thrombin time; UA, uric acid; USG, urine specific gravity. a p < 0.05 considered statistically significant. b To control the Type I errors, the significance level was adjusted, with p < 0.0167 (0.05/3) considered statistically significant. Comparison of laboratory indices among patients with CVT during pregnancy and the puerperium (Group 1), healthy pregnant or puerperal women (Group 3), and healthy female controls without pregnancy and puerperium (Group 4). Note: 1—Group 1 versus Group 3; 2—Group 1 versus Group 4; 3—Group 3 versus Group 4. Abbreviations: APTT, activated partial thromboplastin time; Cr, creatinine; CRP, C‐reactive protein; D‐D, D‑dimer; Fib, fibrinogen; IL‑6, interleukin‐6; LMR, lymphocyte‑to‑monocyte ratio; NLR, neutrophil‐to‐lymphocyte ratio; PLR, platelet‑to‑lymphocyte ratio; PT, prothrombin time; SII, systemic immune‑inflammation index; TT, thrombin time; UA, uric acid; USG, urine specific gravity. p < 0.05 considered statistically significant. To control the Type I errors, the significance level was adjusted, with p < 0.0167 (0.05/3) considered statistically significant. Inflammatory Markers Inflammation markers were markedly elevated in Group 1 relative to Groups 2 and 4, including neutrophil count (6.8 [4.2, 9.6] vs. 3.4 [2.1, 4.1] vs. 2.9 [1.9, 3.8] × 109/L), NLR (4.5 [2.5, 8.8] vs. 1.8 [1.3, 2.6] vs. 1.6 [1.2, 2.1]), SII (877.4 [374.0, 2029.9] vs. 443.1 [340.1, 652.5] vs. 360.7 [215.6, 530.7]), CRP (14.5 [5.8, 22.5] vs. 2.0 [1.8, 4.0] vs. 1.5 [1.0, 2.0] mg/L) and IL‐6 (8.8 [6.1, 22.8] vs. 2.6 [1.5, 5.5] vs. 2.4 [1.5, 3.4] pg/mL), all p < 0.05 (Table 2). Conversely, LMR was significantly lower in Group 1 (3.7 ± 2.0) than that in Group 2 (5.3 ± 2.2, p = 0.003) and Group 4 (6.1 ± 2.3, p < 0.001), while PLR did not differ significantly among the groups. Compared with Group 3, inflammatory indices, such as neutrophil count, NLR, SII and CRP, were comparable in Group 1 (all p > 0.05), but these markers in both Groups 1 and 3 were significantly elevated relative to Group 4 (all p < 0.001; detailed in Table 3). LMRs were similar in Group 1 (3.5 [2.2, 5.0]) and Group 3 (3.2 [2.5, 4.3], p = 0.771), yet both were lower than that in Group 4 (6.1 [4.3, 7.7], p < 0.001). PLR did not differ across the three groups. Dehydration‐Related Indices Compared with Groups 2 and 4, Group 1 exhibited lower Cr levels (Group 1 vs. Group 2 vs. Group 4 = 40.0 [38.0, 50.3] vs. 47.5 [44.0, 53.0] vs. 51.5 [41.8, 58.3] μmol/L, p = 0.024; and 0.002, respectively). Additionally, Group 1 had lower urea levels (2.9 ± 1.3 vs. 4.1 ± 1.2 mmol/L, p < 0.001), plasma Na+(139.4 [136.8, 141.4] vs. 141.1 [140.0, 142.0] mmol/L, p = 0.007), and plasma osmolality (293.4 [288.6, 298.4] vs. 297.9 [296.2, 299.5] mOsm/(kg·H2O), p = 0.001) than Group 4, and a higher proportion of subjects with elevated USG (USG > 1.03, 33.3% vs. 0.0%, p = 0.001). Relative to Group 3, the Cr and Urea levels did not differ significantly in Group 1 (p = 0.136 and p = 0.337, respectively). However, the proportion of subjects with USG > 1.03 was higher in Group 1 (33.3%) than in Group 3 (0.0%, p = 0.001). No significant differences were detected among the groups for K+, glucose, UA or UA/Cr ratio. All results are presented in Tables 2 and 3. Associations Between Laboratory Indices and CVT Severity and Prognosis Spearman's correlation analysis conducted on CVT with pregnancy‐puerperium group indicated that D‐dimer levels exhibited a strong correlation with higher NIHSS and mRS scores upon admission (r = 0.600, p = 0.001; r = 0.643, p = 0.001), at 7 days (r = 0.607, p = 0.001; r = 0.557, p = 0.001), and with NIHSS at 3 months (r = 0.366, p = 0.047). A positive correlation was also detected between PT and mRS at admission (r = 0.383, p = 0.037). Inflammatory markers, including neutrophil count, NLR, SII, CRP, and IL‐6, consistently demonstrated positive correlations with greater neurological severity at admission and 7 days (all p < 0.05). Neutrophil count, NLR, and SII were also correlated with NIHSS at 3 months (all p < 0.05). Conversely, LMR was inversely correlated with severity scores throughout all time points (all p < 0.01). Several inflammatory indices (neutrophil count, monocyte count, NLR, and LMR) were additionally associated with mental symptoms at 3 months (all p < 0.05). Among dehydration‐related parameters, plasma osmolality > 310 mOsm/(kg·H2O) was positively correlated with NIHSS and mRS at 7 days (r = 0.410, p = 0.024; r = 0.404, p = 0.027) and with NIHSS at 3 months (r = 0.535, p = 0.002), while USG was associated with mental symptoms at 3 months (r = 0.421, p = 0.023). Neither mRS at 3 months nor residual somatic symptoms at 3 months showed significant correlations with any of the evaluated laboratory indices. Moreover, no significant associations were found between other dehydration markers, including creatinine, urea, Na+, K+, glucose, UA, UA/Cr ratio, or hematocrit, and any of the severity or outcome measures. All results are presented in Table 4. TABLE 4Associations between indices and severity/prognosis of CVT during pregnancy and puerperium.IndicesNIHSS at admissionmRS at admissionNIHSS at 7 daysmRS at 7 daysNIHSS at 3 monthsmRS at 3 monthsResidual somatic symptoms at 3 monthsMental symptoms at 3 months Spearman's rank correlation coefficient, r, p Coagulation−relatedPT0.268, 0.1520.383 a , 0.0370.302, 0.1050.329, 0.0760.284, 0.1280.308, 0.0970.247, 0.1890.212, 0.261APTT−0.358, 0.052−0.292, 0.118−0.158, 0.406−0.186, 0.3240.154, 0.4160.297, 0.1120.173, 0.3600.016, 0.935TT−0.231, 0.220−0.151, 0.425−0.097, 0.612−0.106, 0.5770.010, 0.9600.135, 0.4770.120, 0.5290.088, 0.644Fib0.245, 0.1920.119, 0.5310.092, 0.631−0.005, 0.981−0.270, 0.150−0.046, 0.808−0.012, 0.952−0.026, 0.892D−D0.600 b , 0.0010.643 b , 0.0010.607 b , 0.0010.557 b , 0.0010.366 a , 0.0470.042, 0.824−0.042, 0.8240.191, 0.312Inflammation−relatedneutrophil0.744 b , 0.0010.719 b , 0.0010.632 a , 0.0010.502 b , 0.0050.376 a , 0.0410.200, 0.2890.177, 0.3490.450 a , 0.013leukomonocyte−0.619 b , 0.001−0.550 b , 0.002−0.548 b , 0.002−0.446 a , 0.013−0.443 a , 0.014−0.150, 0.428−0.135, 0.478−0.160, 0.398monocyte0.323, 0.0820.189, 0.3170.386 a , 0.0350.323, 0.0810.458 a , 0.0110.247, 0.1890.301, 0.1060.414 a , 0.023NLR0.801 b , 0.0010.727 b , 0.0010.699 b , 0.0010.587 b , 0.0010.472 b , 0.0080.243, 0.1960.196, 0.2980.419 a , 0.021LMR−0.599 b , 0.001−0.486 b , 0.007−0.600 b , 0.001−0.490 b , 0.006−0.549 b ,0.002−0.189, 0.318−0.227, 0.227−0.377 a , 0.040PLR0.590 b , 0.0010.490 b , 0.0060.591 b , 0.0010.342, 0.0640.327, 0.0770.135, 0.4780.212, 0.2610.129, 0.496SII0.794 b , 0.0010.721 b , 0.0010.714 b , 0.0010.486 b , 0.0060.414 a , 0.0230.166, 0.3820.196, 0.2980.357, 0.053CRP0.712 b , 0.0010.676 b , 0.0010.678 b , 0.0010.512 b , 0.0040.309, 0.0970.201, 0.2880.116, 0.5430.176, 0.352IL−60.555 b , 0.0020.574 b , 0.0010.445 a , 0.0160.430 a , 0.0200.051, 0.7930.206, 0.2830.239, 0.2110.240, 0.210Dehydration−relatedCr0.045, 0.8120.175, 0.3550.073, 0.7000.045, 0.815−0.014, 0.9390.035, 0.8550.093, 0.6260.187, 0.324Urea0.010, 0.9570.092, 0.6310.067, 0.725−0.014, 0.943−0.087, 0.649−0.185, 0.328−0.131, 0.4900.134, 0.479USG0.210, 0.2740.215, 0.2630.228, 0.2330.174, 0.3660.245, 0.2010.343, 0.0690.240, 0.2110.421 a , 0.023Hematocrit, %−0.108, 0.571−0.110, 0.562−0.050, 0.7950.102, 0.590−0.144, 0.4460.266, 0.1560.327, 0.0770.181, 0.339Na+ −0.119, 0.5330.068, 0.7200.045, 0.8140.065, 0.7310.067, 0.723−0.081, 0.671−0.031, 0.871−0.114, 0.549K+ 0.247, 0.1880.296, 0.1120.037, 0.845−0.127, 0.5050.222, 0.239−0.308, 0.097−0.439, 0.015−0.098, 0.606Glucose0.338, 0.0670.448 a , 0.0130.398 a , 0.0300.377 a , 0.0400.154, 0.416−0.104, 0.585−0.135, 0.4780.315, 0.090Uric acid0.166, 0.3890.124, 0.5210.031, 0.8710.059, 0.7610.203, 0.2900.272, 0.1530.289, 0.1290.207, 0.281UA/Cr0.104, 0.5920.004, 0.982−0.012, 0.949−0.010, 0.9600.234, 0.2220.206, 0.2830.198, 0.3030.044, 0.822Plasma osmolality, mOsm/(kg·H2O)−0.054, 0.7770.138, 0.4660.093, 0.6250.079, 0.6780.077, 0.686−0.127, 0.503−0.096, 0.6130.047, 0.807USG > 1.03, n (%)0.299, 0.1090.295, 0.1130.262, 0.1610.160, 0.3980.354, 0.0550.283, 0.1300.141, 0.4560.253, 0.177Plasma osmolality > 310 mOsm/(kg·H2O)0.308, 0.0980.343, 0.0630.410 a , 0.0240.404 a , 0.0270.535 b , 0.0020.267, 0.1530.267, 0.1530.239,0.203Abbreviations: APTT, activated partial thromboplastin time; Cr, creatinine; CRP, C‐reactive protein; D‐D, D‑dimer; Fib, fibrinogen; LMR, lymphocyte‑to‑monocyte ratio; NLR, neutrophil‐to‐lymphocyte ratio; PLR, platelet‑to‑lymphocyte ratio; PT, prothrombin time; SII, systemic immune‑inflammation index; TT, thrombin time; UA, uric acid; USG, urine specific gravity. a p < 0.05. b p < 0.01. Associations between indices and severity/prognosis of CVT during pregnancy and puerperium. Abbreviations: APTT, activated partial thromboplastin time; Cr, creatinine; CRP, C‐reactive protein; D‐D, D‑dimer; Fib, fibrinogen; LMR, lymphocyte‑to‑monocyte ratio; NLR, neutrophil‐to‐lymphocyte ratio; PLR, platelet‑to‑lymphocyte ratio; PT, prothrombin time; SII, systemic immune‑inflammation index; TT, thrombin time; UA, uric acid; USG, urine specific gravity. p < 0.05. p < 0.01. Discussion In this study, we systematically characterized clinical features and laboratory profiles of CVT during pregnancy and the puerperium, using both pathological and physiological control groups. Several key findings emerge. First, CVT with pregnancy‐puerperium presents with a more acute and clinically severe phenotype, characterized by earlier hospital admission, a higher burden of neurological symptoms, and preferential involvement of critical venous sinuses. Second, CVT with pregnancy‐puerperium occurs in the context of pregnancy‐related hypercoagulability, immune‐inflammatory activation, and fluid‐balance alterations, with overlap between pathological changes and physiological adaptations. Third, biomarkers from each of these pathways, particularly D‐dimer, inflammatory indices, and selected dehydration parameters, were significantly associated with neurological severity and outcomes, underscoring their potential prognostic relevance. CVT With Pregnancy‐Puerperium as a Clinically Severe Phenotype CVT with pregnancy‐puerperium presented significantly earlier after symptom onset than those CVT without pregnancy‐puerperium, consistent with an acute disease phase that has been associated with worse outcomes [20]. Clinically, these patients exhibited higher frequencies of seizures, impaired consciousness, and focal neurological deficits, together with a tendency toward involvement of major venous structures such as the superior sagittal sinus and straight sinus. Thrombosis in these locations is known to compromise global venous drainage and has been linked to unfavorable prognosis [8, 21]. Although median NIHSS and mRS scores at admission did not differ significantly between the two CVT groups, the higher upper quartiles observed in CVT with pregnancy‐puerperium suggest a subgroup with particularly severe neurological involvement. Collectively, these findings indicate that CVT with pregnancy‐puerperium represents a high‐risk clinical phenotype requiring heightened vigilance and early intervention. Coagulation Markers in Pregnancy‐Related CVT and Their Overlap With Physiological Pregnancy Adaptations Pregnancy and the puerperium are well‐established hypercoagulable states, characterized by increased levels of procoagulant factors and reduced fibrinolytic activity [16, 17]. In the present study, fibrinogen and D‐dimer levels in patients with CVT during pregnancy‐puerperium were significantly higher than those in patients with CVT outside pregnancy‐puerperium and healthy nonpregnant female controls. However, when compared with healthy pregnant or puerperal women, fibrinogen was lower in the CVT with pregnancy‐puerperium group, and D‐dimer levels did not differ significantly between the two groups. These findings indicate a substantial overlap between CVT‐related coagulation activation and physiological pregnancy‐related hemostatic adaptations. Notably, D‐dimer showed strong and consistent correlations with neurological severity at admission and early follow‐up, supporting its role as a dynamic marker of disease burden in CVT with pregnancy‐puerperium. The seemingly paradoxical prolongation of PT, APTT, and TT observed in CVT with pregnancy‐puerperium compared with healthy pregnant or puerperal controls likely reflects the influence of early anticoagulant exposure rather than an absence of hypercoagulability, highlighting the limitations of conventional clotting times in this clinical context. Inflammation: Distinguishing Pathological Signal From Pregnancy Physiology A key challenge in CVT with pregnancy‐puerperium is distinguishing pathological inflammation from physiological immune modulation. While pregnancy itself is associated with low‐grade systemic inflammation, our findings indicate that inflammation in CVT with pregnancy‐puerperium carries distinct clinical significance [18, 19]. Although inflammatory markers such as neutrophil count, NLR, SII, and CRP were similarly elevated in CVT with pregnancy‐puerperium and healthy pregnancy‐puerperium women, these inflammatory indices were significantly correlated with neurological severity and early outcomes among patients with CVT during pregnancy‐puerperium. Inflammation associated with pregnancy‐related CVT may reflect additional disease‐specific processes, potentially mediated by thromboinflammatory mechanisms that exacerbate venous congestion, blood–brain barrier disruption, and secondary brain injury. Furthermore, the observed associations between inflammatory indices and residual mental symptoms at 3 months align with emerging evidence linking systemic inflammation during pregnancy and the puerperium period to long‐term neuropsychiatric sequelae [22]. These findings raise the possibility that targeted modulation of excessive inflammation, in carefully selected severe cases, may represent a valuable adjunct to anticoagulation. Relative Dehydration Despite Physiological Plasma Expansion At first glance, dehydration‐related findings in CVT with pregnancy‐puerperium may appear counterintuitive, given the plasma volume expansion characteristic of pregnancy [23]. However, our results suggest a state of relative or functional dehydration, best captured by elevated USG and plasma osmolality rather than traditional renal markers. Creatinine and urea levels were lower in CVT with pregnancy‐puerperium, likely reflecting pregnancy‐related hemodilution and reduced muscle mass or nutritional intake, particularly in the context of conditions such as hyperemesis gravidarum [24]. Importantly, elevated plasma osmolality was associated with worse neurological outcomes at 7 days and 3 months, indicating that relative dehydration may exacerbate venous stasis, impair cerebral venous outflow, and contribute to disease severity. These findings underscore the limitation of relying solely on creatinine or urea to assess hydration status in pregnant patients and suggest that focused assessment of urine concentration and osmolality may provide clinically meaningful information. Clinical Implications and Future Directions Taken together, our findings support the concept that CVT during pregnancy‐puerperium occurs against a background of physiological hypercoagulability, immune‐inflammatory activation, and pregnancy‐related changes in fluid balance. An important clinical implication of this study is that several conventional coagulation and inflammatory markers showed substantial overlap between patients with CVT during pregnancy‐puerperium and healthy pregnant or puerperal women. Therefore, absolute elevations in markers such as fibrinogen, D‐dimer, neutrophil count, NLR, SII, and CRP should not be interpreted as disease‐specific evidence of CVT in isolation. This overlap highlights the diagnostic challenge of distinguishing pathological CVT‐related changes from physiological pregnancy‐related adaptations. The relatively high proportion of first‐trimester cases in the CVT with pregnancy‐puerperium group should also be interpreted cautiously. Although pregnancy‐related CVT has generally been reported more frequently in late pregnancy and the puerperium, early pregnancy may still represent a vulnerable period in selected individuals, particularly when pregnancy‐related hypercoagulability is combined with additional triggers such as reduced fluid intake, hyperemesis, relative dehydration, immobilization, or underlying thrombophilia. This observation should therefore be regarded as a cohort‐specific finding rather than evidence of a different epidemiological distribution. These findings suggest that conventional biomarkers may have greater value for risk stratification and prognostic assessment than for standalone diagnostic discrimination. Although several inflammatory and coagulation markers overlapped between pregnancy‐related CVT and healthy pregnancy‐puerperium, D‐dimer and inflammatory indices were significantly associated with neurological severity and early outcomes within the CVT with pregnancy‐puerperium group. Thus, once CVT is clinically suspected or confirmed, these markers may help identify patients who require closer neurological monitoring and more intensive supportive management. Future studies should focus specifically on the differences between pregnant or puerperal women with and without CVT, with particular attention to gestational and puerperal timing. Prospective studies with larger sample sizes, careful matching for gestational age or puerperal stage, and longitudinal biomarker assessment are needed to determine whether dynamic changes in coagulation, inflammation, and hydration status are more informative than single‐time‐point measurements. In addition, comprehensive thrombophilia testing, assessment of endothelial activation and thromboinflammatory markers, and imaging‐based evaluation of thrombus burden, venous sinus anatomy, and venous flow characteristics may help clarify why only some pregnant or puerperal women develop CVT despite laboratory profiles that overlap with physiological pregnancy‐related changes. Such efforts may ultimately refine individualized risk assessment and management strategies for this high‐risk population. Limitations There are several limitations to our study. First, this was a retrospective, single‐center study with a relatively small sample size, which may have introduced selection bias and limited the generalizability of our findings. Second, the distribution of gestational and puerperal stages differed between patients with CVT during pregnancy‐puerperium and healthy pregnant or puerperal controls. In particular, first‐trimester cases were overrepresented in the CVT group, whereas third‐trimester cases were more common among healthy pregnant or puerperal controls. Because coagulation, inflammatory, and fluid‐balance markers vary across pregnancy and the puerperium, this imbalance may have influenced between‐group comparisons. Third, dehydration status was assessed using indirect laboratory markers, and the follow‐up period was limited to 3 months. Future prospective studies with larger cohorts, gestational age‐ or puerperal stage‐matched controls, more direct assessment of hydration status, and longer follow‐up are needed to validate our findings. Conclusion In this study, we demonstrate that CVT occurred during pregnancy‐puerperium is characterized by a synergistic triad of exaggerated hypercoagulability, pathological systemic inflammation, and relative dehydration, with overlap between pathological CVT‐related changes and physiological pregnancy adaptations. Importantly, biomarkers reflecting each of these pathways, particularly D‐dimer, inflammatory indices, and elevated plasma osmolality, were consistently associated with acute neurological severity and outcomes. Author Contributions Xiaoming Zhang: writing – original draft, writing – review and editing, data collection, conceptualization. Zilin Xu: writing – data collection. Ran Duan: writing – data collection. Chunxiao Lu: writing – data collection. Da Zhou: writing – review and editing. Chen Zhou: writing – review and editing, supervision. Ran Meng: writing – review and editing, supervision. Xunming Ji: writing – funding acquisition, review and editing, supervision. All authors reviewed and edited the manuscript and approved the final version of the manuscript. Funding This work was supported by the Fundamental and Interdisciplinary Disciplines Breakthrough Plan of the Ministry of Education of China, (Grant no. JYB2025XDXM603). Ethics Statement Ethical approval for this study was obtained from the Institutional Review Board of Xuanwu Hospital, Capital Medical University [2022; 004]. Consent Written informed consent for publication of clinical details was obtained from all participants. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgments The authors would like to thank the patients and their families for supporting this work. They gratefully acknowledge the contributions of the neurology, neuroradiology, and obstetrics teams at Xuanwu Hospital. Funding Statement This work was funded by Fundamental and Interdisciplinary Disciplines Breakthrough Plan of the Ministry of Education of China grant JYB2025XDXM603. Contributor Information Chen Zhou, Email: chenzhou2013abc@163.com. Ran Meng, Email: victor65@126.com. Xunming Ji, Email: jixunming1989@163.com. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.